Miura, Naoki
Morishita, Koji
Yasuda, Takamasa
Akiduki, Saori
Matsumoto, Hideki http://orcid.org/0000-0002-8057-9598
Funding for this research was provided by:
International Council on Amino Acid Science (ICAAS), Belgium and Japan branch of ICAAS, Japan.
Article History
Received: 30 June 2022
Accepted: 13 December 2022
First Online: 26 December 2022
Declarations
:
: N.M. declares no conflict of interest. T.Y. and H.M. are employed by Ajinomoto Co., Inc. (Japan). K.M. and S.A. are employed by Kyowa Hakko Bio Co., Ltd. (Japan).
: The trials were conducted according to the guidelines of the Declaration of Helsinki and approved by the Miura Medical Clinic Ethic Review Committee (ethical approval code R1913 of 20 February 2020). The trials were registered on 3 May 2020 in the clinical trial registration system operated by the University Hospital Medical Information Network Research Center under UMIN 000040281. In conducting this trial, the 1.5th edition of the protocol was prepared on 9 June 2021, to include COVID-19 infection control. The study was approved by the ethics committee on 21 June 2021.
: Informed consent was obtained from all subjects involved in the study.